{"id":"NCT00719680","sponsor":"CSL Behring","briefTitle":"Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)","officialTitle":"A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2008-07-22","resultsPosted":"2013-01-25","lastUpdate":"2014-04-02"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"IgPro20","otherNames":["IgG with Proline"]}],"arms":[{"label":"IgPro20","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.","primaryOutcome":{"measure":"Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)","timeFrame":"For the duration of the study, up to approximately 104 weeks","effectByArm":[{"arm":"IgPro20","deltaMin":0.06,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["24412910"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":21},"commonTop":["Sinusitis","Injection site reaction","Infusion site reaction","Nasopharyngitis","Oropharyngeal pain"]}}